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Background: During osteoclastogenesis, the maturation of osteoclast (OC) progenitors is stimulated by the
receptor activator of nuclear factor-κB ligand (RANKL). Excess OC production plays a critical role in the pathogenesis of
inflammatory bone disorders. Conversely, the inhibition of abnormal OC proliferation reduces inflammation-induced
bone loss. Low concentrations of carbon monoxide (CO) are known to decrease inflammation and OC-mediated bone
erosion but the molecular mechanism is unknown.
Results: To obtain insight into the biological function of CO, cultured RANKL-treated RAW 264.7 cells were used
in an in vitro experimental model of osteoclastogenesis. The results showed that CO inhibited: 1) tartrate-resistant
acid phosphatase (TRAP)-positive cell formation; 2) F-actin ring production; 3) c-fos pathway activation; 4) the
expression of cathepsin K, TRAP, calcitonin receptor, and matrix metalloproteinase-9 mRNAs; 5) the expression of
nuclear factor of activated T cells, cytoplasmic, calcineurin-dependent 1 in translation. Protein-protein interaction
analysis predicted mitogen-activated protein kinase kinase kinase 4 as the controlling hub.
Conclusions: Low-concentrations of CO (250 ppm) may inhibit osteoclastogenesis. Data from STRING- and IPA-based
interactome analyses suggested that the expression of proteins with the functions of signal transduction, enzymes, and
epigenetic regulation are significantly altered by CO during RANKL-induced osteoclastogenesis. Our study provides
the first interactome analysis of osteoclastogenesis, the results of which supported the negative regulation of
OC differentiation by CO.
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Bone homeostasis is strictly regulated through a dynamic
balance between osteoblastogenesis (bone formation) and
osteoclastogenesis (bone resorption) [1-5]. In the former,
osteoblasts (OBs) control bone formation through the
synthesis of bone matrix proteins. In osteoclastogenesis,
large multinucleated osteoclasts (OCs) remove the miner-
alized matrix of bone tissue, resulting in bone resorption.
OCs are derived from hematopoietic precursors of the
monocyte-macrophage lineage, and their differentiation* Correspondence: pan1628@yahoo.com
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reproduction in any medium, provided the oris regulated by macrophage colony-stimulating factor
(M-CSF) [6]. Mutations in the M-CSF gene induce
defects in the formation of macrophages and OCs, which
suggests that immune cells and bone cells are derived
from the same progenitors [7].
The receptor activator of nuclear factor (NF)-κB ligand
(RANKL), a member of the tumor necrosis factor
(TNF) family, regulates OC maturation and differentiation
[8,9]. Bone-forming OBs express RANKL as do activated
T cells which indicates a role for the immune system in
osteoclastic bone resorption [9,10]. In addition, many in-
flammatory cytokines are known to modulate RANKL
expression, including TNF-α [9,11], and the RANKL
dependence of several inflammatory bone diseases has
been reported [10]. Bone dysfunction may also arisetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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by directly triggering osteoclastogenesis [12].
Osteoclasts express the receptor activator of NF-κB
(RANK), a type I membrane protein. Thus, the RANKL/
RANK signaling cascade regulates not only the matur-
ation of OC progenitors, but also the activity of OCs in
normal bone remodeling [13,14]. Given the critical func-
tions of OCs, an understanding of the process that con-
trol their differentiation is required for the successful
treatment of many bone pathologies.
Carbon monoxide (CO) is an invisible and odorless gas
with a binding affinity for heme that is 240 times higher
than that of oxygen. Concentrations of CO in the air
exceeding 3% (30000 ppm) are usually lethal [15,16]. CO
is endogenously produced by mammals, by the degrad-
ation of heme, albeit in very low concentrations [17,18].
Interestingly, however, in small amounts (250 ppm) CO
exhibits anti-apoptosis, anti-proliferation, anti-inflamma-
tory, and many other biological activities [19-22]. For
example, CO-releasing molecule-2 dose-dependently
inhibits RANKL-induced osteoclastogenesis [23].
Mouse leukemic monocyte macrophage RAW 264.7 cells
are derived from Abelson-virus-treated mice ascites and
recognized as pre-OCs [24]. Following their stimulation
with RANKL, these cells produce OCs in a pathway
involving mitogen-activated protein kinases (MAPKs),
extracellular-regulated kinase (ERK), p38, jun N-terminal
kinase (JNK), and c-fos [25-27]. In this study, we used
RANKL-treated RAW264.7 cells as an vitro model to
investigate the effect of CO on the signaling pathway of
RANKL-induced osteoclastogenesis. In addition, in an
approach using interactomics to obtain a protein-protein
interaction (PPI) network, we derived a genome-scale PPI
map to deduce the potential signaling pathways and mem-
ber proteins involved in the differentiation and activation
of OCs, and the effects of CO on these pathways [28].
Results
Inhibition of RANKL-induced osteoclastogenesis in RAW
264.7 cells by low-dose CO without preventing growth or
inducing apoptosis
RAW 264.7 cells incubated with 10, 15, and 20 ng
RANKL/mL for 96 h gave rise to TRAP(+) multinucleated
cells in a dose-dependent manner. When these RANKL-
treated progenitor cells were exposed to 250 ppm CO, the
formation of TRAP(+) multinucleated cells was inhibited
by 73 + 5% (10 ng/mL), 70+ 5% (15 ng/mL), and 41+ 10%
(20 ng/mL) (Figure 1C,D), We also check the effects of
CO on osteoclastogenesis in bone marrow macrophages
and the results are the same as RAW cells (Additional
file 1). Moreover, after incubation with 250 ppm CO for 72
or 96 h, RANKL-treated RAW 264.7 cells retained their
ability to proliferate and the expression of activated caspase-
3, a marker of apoptosis, was not induced (Figure 1B).CO-induced inhibition of F-actin ring formation by
osteoclasts
Formation of the F-actin ring by OCs is a necessary step
in bone resorption. As shown in Figure 2A and Figure 2B,
in RAW 264.7 cells treated with 20 ng RANKL/mL and
250 ppm CO for 96 h, F-actin ring formation was reduced
(Additional file 2). A similar inhibitory effect of osteoclast
pit formation, an indicator of bone resorption, was ob-
served on dentin discs in the CO but not the Air group.CO-induced suppression of RANKL-induced JNK and c-jun
phosphorylation, and c-fos but not IκB-α expression
The activation of NF-κB plays an important role in the
differentiation of pre-OCs. As shown in Figure 3A, in
RAW 264.7 cells exposed to 20 ng RANKL/mL and
250 ppm CO there was no change in the expression of
IκB-α, which is normally induced by NF-κB and serves as
its inhibitor. Furthermore, this same dose of CO inhibited
the phosphorylation of RANKL-induced JNK and c-jun
but not that of either ERK or mitogen-activated protein
kinase p38 (p38) within 120 min (Figure 3B). The same
concentration of CO down-regulated the expression of c-
fos in similarly treated RAW 264.7 cells (Figure 3C).CO-induced reduction of Acp5, Ctsk, Calcr, Mmp9, and
NFATc1 expression
RANK is expressed on the cell surfaces of pre-OCs and
OCs. As shown in Figure 4A, RANK mRNA expression
in RAW 264.7 cells was not affected by 250 ppm CO
within 96 h. Tartrate-resistant acid phosphatase (Acp5),
the calcitonin receptor (Calcr), cathepsin K (Cstk), and
matrix metalloproteinase-9 (mmp9) are unique markers
of mature OCs. In RAW 264.7 cells treated with 20 ng
RANKL/mL for 96 h, 250-ppm CO reduced the mRNA
expression levels of all four genes (Figure 4B). Moreover,
the expression of the protein nuclear factor of activated
T cells, cytoplasmic, calcineurin-dependent 1 (NFATc1),
which is the master regulator of osteoclastogenesis, was
likewise significantly reduced (Figure 4C).Critical roles of MAP3K4 and the JNK signaling pathway
in RANKL-induced osteoclastogenesis
The STRING database was used to construct a PPI map
of RANKL-induced osteoclastogenesis. The map showed
three protein clusters joined by mitogen-activated pro-
tein kinase kinase kinase 4 (MAP3K4) as a potential hub
protein (Figure 5A). Using IPA software (see Methods),
we identified the JNK protein family signaling pathway as
a potential participant in the maturation of RAW 264.7
cells treated with 20 ng RANK/mL and exposed to
250 ppm CO (Figure 5B).
Figure 1 CO reduces osteoclastogenesis by RANKL-treated RAW 264.7 cells in vitro. (A) RAW 264.7 cells treated with 10, 15, and 20 ng
RANKL/mL and examined by TRAP staining after 96 h. (B) Upper panel, RAW 264.7 cells exposed to air or 250 ppm CO for 96 h and then stained with
0.05% methylene blue, as described in Methods. The data are the mean from three experiments with triplicate samples; bars, +SD. Lower panel,
Western blot analysis of activated caspase 3 expression by RAW 264.7 cells. (C) TRAP staining of RAW 264.7 cells treated with 20 ng RANKL/mL and
then exposed to 250 ppm CO. (D) Bar chart showing the inhibitory effect of CO (250 ppm) on RAW 264.7 cells treated as in (C).
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The potential benefits of CO have led to many studies of
its possible therapeutic applications, which have been
examined in different disease models. Sato et al. showed
that CO prolonged the survival of mouse-to-rat cardiac
grafts [29]. In mice with ischemic lung injury, the inhal-
ation of CO was reported to prevent their death [30]. The
protective effects of CO have also been demonstrated in
animal models of autoimmune diseases [31-33].
Bone remodeling is a tightly regulated cycle involving
the formation of bone by OBs and its resorption by OCs.
The latter are monocyte-macrophage lineage-derived
cells whose differentiation and maturation is regulated
by OBs via RANKL. Excessive bone resorption, initiated
by proinflammatory cytokines, also proceeds through
RANKL and leads to abnormal bone destruction. Given the
involvement of OCs in these processes, an understanding
of their formation and function is crucial to prevent bone
loss in inflammatory diseases such as arthritis.
In our study, small doses of exogenous CO not only
reduced the degree of inflammation and the expression
of RANKL. Consistent with these results, CO was shown
to reduce joint destruction in a murine model of collagen-
induced arthritis [34]. However, the effect of CO
on RANKL-induced osteoclastogenesis has not beeninvestigated. In this study, the differentiation of pre-OC
murine macrophage-like RAW 264.7 cells into multinu-
cleated OCs was stimulated using recombinant RANKL
protein. This system was then used to examine the
potential role of CO in osteoclastogenesis. In these
experiments, the expression of several OC markers was
examined, including the glycosylated monomeric metal-
loenzyme TRAP, which is expressed at high levels by.
differentiated OCs. In the presence of 250 ppm CO,
TRAP expression by RANKL-stimulated RAW 264.7 cells
that had differentiated into TRAP (+) multinucleated OCs
was blocked (Figure 1). Cytoskeletal reorganization in
mature functioning OCs, including the formation of
dot-like F-actin rings, was likewise inhibited in RANKL-
treated RAW 264.7 cells, whereas their growth was not,
nor was apoptosis induced (Figure 2). Thus, collectively,
our data show that one of the effects of CO is to inhibit
the maturation of pre-OCs induced by RANKL.
The regulatory mechanisms by which RANKL and
its intracellular signaling pathways enable pre-OCs to
differentiate have been extensively studied [8,35,36].
RANKL binds to RANK expressed on the plasma me-
mbrane of OC precursors [25,27,37-41], which then
activates an intricate signaling cascade that includes
NF-κB, c-fos, c-jun, MAPKs, and NFATc1 [36,42]. Support
Figure 2 CO inhibits F-actin ring formation by RANKL-treated
RAW 264.7 cells. (A) Effect of 250 ppm CO on the distribution of
clustered F-actin filaments in RANKL-treated RAW 264.7 cells. Arrows
show the position of the F-actin ring. (B) Pit formation assay of
RANKL-treated RAW 264.7 cells cultured on dentin discs and
incubated with air or CO.
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from a previous study in which inhibition of c-fos ex-
pression in mice blocked OC differentiation and caused
osteopetrosis [39]. IκB-α binds to NF-κB in the cytoplasm,
thus maintaining the protein in an inactive form and
tightly regulating its transcriptional activity. In our study,
CO had no effect on the NF-κB (IκB-α) pathway, as shown
in a western blot analysis of IκB-α expression and mea-
surements of RANK mRNA levels (Figure 3A, 4A). How-
ever, CO did inhibit the maturation of RANKL-treated
RAW 264.7 cells. So what is the nature of the signaling
pathway involved in CO-inhibited osteoclastogenesis?
Given the CO-mediated reductions in c-jun and JNK
phosphorylation and c-fos expression in RANKL-treated
RAW 264.7 cells (Figure 3B, Figure 3C), CO could inhibit
RANKL-induced osteoclastogenesis by deactivating AP-1,
thus down-regulating c-fos, a component of this complex.
The activity of AP-1 (containing c-fos) is crucial for the
auto-amplification of NFATc1 [43], which is induced
and activated by RANKL signaling during the terminal
differentiation of OCs [36,42]. Among the OC-specific
genes regulated by NFATc1 are Acp5, Calcr, Cstk, andmmp9 [43-45]. In the presence of CO, the mRNA levels of
all four genes was significantly reduced (Figure 4B).
In addition, CO inhibited the translation of NFATc1
(Figure 4C). Together, these findings suggest that CO
acts on the MAPK pathway to inhibit osteoclastogenesis
by RAW 264.7 cells induced to differentiate by stimulation
with RANKL.
Interactomics yields deep insights into the molecular
mechanism of diseases and their intracellular signaling
pathways [28] but, to the best of our knowledge, it has
not been used to profile osteoclastogenesis. In this study,
a STRING database analysis of RANKL-induced osteo-
clastogenesis established a PPI map with three clusters
(Figure 5A). Cluster I is a highly symmetric, connected
protein cluster with strong interactions. It contains Fos,
Jun, retinoblastoma binding protein 7 (RBBP7), nuclear
factor of kappa light polypeptide gene enhancer in B-cells
inhibitor, beta (NFKBIB), CREB binding protein (CREBBP,
CBP), peroxisome proliferator-activated receptor gamma
(PPARG), NFATc1, and MAPKs. RBBBP7, also called
RbAp46, is a histone H4 binding protein that binds to the
c-fos transcriptional activation site to inhibit cell mitosis
[46]. We found that the prevention of differentiation by
RANKL-treated RAW264.7 cells was accompanied by a
decrease in c-fos expression, which suggests that CO
alters the action of RBBBP7 on c-fos during osteoclas-
togenesis. Another cluster I protein, the nuclear receptor
PPARG, is pivotal for adipogenesis and interacts with
histone deacetylase 3 (HDAC3) [47], contained in cluster
II along with HDAC7. HDACs catalyze the removal of
acetyl groups from an ε-N-acetyl lysine amino acid on
histones, which are contained in cluster III. In a previous
report the use of shRNA to inhibit HDAC3 expression
also inhibited OC formation whereas similar inhibition
of HDAC7 accelerated OC differentiation [48]. These
findings suggest that the balance between HDAC3 and
HDAC7 expression decides the fate of pre-OCs exposed
to CO. Among the cluster III histones are the histone
H2A family (H2AF) members X and Z (H2AFX, H2AFZ),
and histone H3 family member 3A (H3F3A). Histones are
highly alkylated and comprise the major protein compo-
nent of chromatin. The epigenetic regulation of histones
by methylation and acetylation may provide regulatory
control of OC differentiation. For example, the expres-
sion of NFATc1 induced by RANKL is associated with
the demethylation of trimethylated histone H3 lysine 4
and lysine 27 (H3K4me3, H3K27me3) [49].
Proteins identified as controlling hubs are major, central
proteins in PPI networks. As shown in Figure 5A, c-Jun
strongly interacted with other proteins in cluster I, such as
jnk1 and jnk2. Furthermore, this cluster interacts with
MAP3K4 (also called MTK1), a protein in the MAPK
pathway, through c-Jun. Abell et al. [50] showed that
MP3K4 regulates jnk1 and jnk2 to control the activity of
Figure 3 CO suppresses JNK and c-jun phosphorylation and c-fos expression in RANKL-treated RAW 264.7 cells. Western blots showing
(A) the expression of IκB-α, as an indicator of NF-κB activity, (B) the phosphorylation of ERK, p38, and JNK, and (C) c-Jun and c-Fos expression.
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Figure 4 CO reduces the expression levels of the genes Acp5, Ctsk, Calcr, and Mmp9 and of the protein NFATc1 but not that of RANK
in RANKL-treated RAW 264.7 cells. (A) Western blot analysis of RANK expression. (B) qRT-PCR analysis of Acp5, Calcr, Cstk, and Mmp9 expression.
(C) Western blot analysis of NFATc1 expression.
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trophoblast stem cells during the epithelial-mesenchymal
transition. In our interactomics analysis, MAP3K4 was
designated as a hub protein that interacts with c-Jun,
thereby controlling the interaction between CBP and
HDAC3 during OC differentiation. PPI maps derived
using the IPA software have been widely used to gain
insight into molecular interactions, signaling pathways,
and pathogenesis [51]. One of the advantages of this
approach is data from a limited number of experiments
can be analyzed. We therefore took advantage of this
method to obtain a global understanding of the signaling
pathways that are activated during osteoclastogenesis in
the presence of CO (Figure 5B). Our results showed that
CO significantly inhibited the expression of the transcrip-
tional factors c-JUN and c-FOS, the protein partners ofAP-1 (Figure 3C), which suggests their involvement in
the CO-mediated blockade of OC differentiation. JNK1
and JNK2, two proteins controlled by MAP2K4, were
shown to interact with JUND and thereby alter the
transcriptional activity of JUN. The IPA PPI showed
that in RANKL-treated RAW264.7 cells exposed to CO,
MAP2K4, a downstream regulator of MAP3K4 [52],
interacts with IκB-α and P38.
Conclusions
In this study, a low concentration of CO (250 ppm) was
shown to inhibit osteoclastogenesis in RANKL-treated
RAW264.7 cells. An interactome identifying the PPI net-
work involved in the observed effects allows the following
conclusions. First, proteins that function as signal transduc-
ers, enzymes, and epigenetic regulators are significantly
Figure 5 The PPI network and signaling pathway analysis. (A) The PPI network, as shown in the interaction view, generated by the STRING
database. Black squares indicate the protein clusters, and the red square the controlling hub, MAP3K4. (B) The computed predicted signaling
pathways that are activated in RANKL-treated RAW 264.7 cells.
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Second, CO inhibits osteoclastogenesis through the MAPK
signaling pathway. Third, STRING predicted that MAP3K4
is a major controlling hub protein. Fourth, the interac-
tomics software IPA not only predicted a critical role for
MAP2K4 but also identified MAP3K4 as a hub protein.
Fifth, STRING and IPA provide overlapping, complemen-
tary information. While the data obtained with these tools
are similar, the latter provided both a more complete PPI
and an easier approach to understanding the behavior of
each protein during CO-regulated osteoclastogenesis. Our
research offers new data and thus new insights into CO-
regulated osteoclastogenesis. However, further detailed
investigations into the molecular mechanisms underlying
this process are needed.Methods
Methylene blue solution, sarkosyl, and the TRAP staining
and leukocyte acid phosphatase assay kits were purchased
from Sigma (St. Louis, MO, USA). Recombinant RANKL
protein was obtained from PeproTech (Rocky Hill, NJ,
USA). Anti-IκB antibody was obtained from Biolegend
(San Diego, CA, USA). Antibodies for phospho-p38,
phospho-JNK, phospho-ERK, phospho-c-jun, and c-fos
were purchased from GeneTex (Irvine, CA, USA). Anti-
RANKL and anti-actin antibodies were obtained from
Abcam (Cambridge, UK), and Sigma, respectively.
Cell culture
RAW 264.7 cells were cultured in DMEM with 10% FCS,
2 mM L-glutamine, 10 units penicillin/mL, and 10 μg
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bator. RAW 264.7 cells were transferred to 100-mm
dishes when they reached 80% confluence and further
grown in the culture medium.
Cell proliferation assay
RAW 264.7 cells were grown in 24-well plates (104 cells/mL
per well). The medium was removed at day 3 and the cells
were stained with methylene blue solution (0.3 mL per
well) at room temperature for 30 min, followed by three
to four washes with Milli-Q water. The cells were then
air dried and dissolved overnight in 1% sarkosyl in
phosphate-buffered saline (PBS, 0.3 mL/well). The cell
solution was transferred to a 96-well plate (0.1 mL/well),
and the absorbance was read at 540 nm using an ELISA
plate spectrophotometer.
In vitro OC differentiation
Cells (104 per well) were grown in 24-well plates and ex-
posed to RANKL (5–20 ng/mL) for 120 h to induce OC
formation [24]. These cells were fixed and then stained
for TRAP expression using a TRAP staining kit accord-
ing to the manufacturer’s protocol. The cells were ob-
served using an Olympus BX51 microscope equipped
with DP controller (ver. 3.3.1.292). Those with more
than three nuclei were identified as TRAP (+) OCs.
CO exposure
The cells were incubated at 37°C in the presence or
absence of 5% CO2. The gas was prepared by using an air
mixer to dilute an initial concentration of 1% (10,000 ppm)
in compressed air with fresh air to obtain a final concentra-
tion of 250 ppm, which was then delivered into the incuba-
tor. A CO analyzer (Siemens Ultramat 23, Germany) with a
sensitivity of 10–600 ppm was used to measure CO levels.
Immunofluorescence analysis
F-actin rings were detected as described previously [53].
Briefly, the cells were fixed with 4% paraformaldehyde,
permeabilized with 0.5% Triton X-100 in PBS, and incu-
bated with an anti-actin antibody at 4°C overnight. After a
PBS wash, the cells were incubated with FITC-conjugated
secondary antibody for 30 min at 37°C and then analyzed
using a Olympus BX51 microscope equipped with a DP
controller (version 3.3.1.292).
Pit formation assay
RAW264.7 cells (1 × 103) were co-cultured with RANKL
on dentin discs (Immunodiagnostic Systems Inc., Fountain
Hills, AR, USA) in a 96-well plate for 72 h in the presence
(CO group) or absence (air group) of CO. Typically, three
discs were prepared per group. To observe the areas con-
taining resorption lacunae, the cells were removed the
discs were incubated in 0.25 M ammonium hydroxide,washed with distilled water, and then stained with 0.5%
(wt/vol) toluidine blue. The resorbed areas were imaged
using a reflective optical microscope (LSM 510, Zeiss).
Western blotting analyses
The cells were washed twice with PBS and protein
extracts of the nucleus and cytosol were prepared using
a ProteoJET cytoplasmic and nuclear protein extraction
kit (Fermentas, Glen Burnie, MD, USA). The extracts
were centrifuged at 10,000 × g for 5 min after which the
supernatants were collected and treated with protease
inhibitors. The protein concentration was determined
using the Bradford protein assay. The extracts (20 μg)
were then dissolved in 6× Laemmli sample loading buffer,
boiled for 10 min, and subjected to SDS-PAGE on a
10% gel. The proteins in the gel were electrotransferred
onto polyvinylidene fluoride membrane (Millipore) with
a semi-dry transfer unit at 20 V for 30 min. After a
blocking step with 5% skim milk in Tris-buffered saline
(TBS; 20 mM Tris base pH 7.6, 150 mM NaCl) containing
1% Tween-20 at room temperature for 1 h, the membrane
was incubated with the primary antibody at room tem-
perature at 4°C overnight. It was then washed three times
for 10 min with TBS containing 1% Tween-20, incubated
with secondary antibody at room temperature for 1 h, and
again washed as before. The immunoblotted protein
bands were visualized by chemiluminescence using Immo-
bilon western chemiluminescent HRP substrate (Millipore,
Billerica, MA, USA) and X-ray film.
Real-time quantitative reverse transcription-polymerase
chain reaction (qRT-PCR) analysis
Trizol reagent was used to isolate total RNA, which was
further eluted with 20 μL of RNase-free water. For cDNA
synthesis, 5 μg of total RNA was reverse transcribed at
42°C for 60 min using RevertAid first-strand cDNA synthe-
sis kit (Fermentas). The reaction was terminated by heating










The Maxima SYBR Green/ROX qPCR master mix kit
(Fermentas) was used for all qRT-PCRs. The reactions
were carried out in a total volume of 20 μL containing
10 μL of 2× Maxima SYBR Green/ROX qPCR, 1 μM of
the primer pair, and 5 μL of cDNA. Thermal cycling
parameters were 95°C for 10 min, 40 cycles of 95°C for
15 sec, and 60°C for 60 s. The samples for each PCR
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as the control. Data sets were analyzed and amplification
plots were obtained automatically by the 7500 Fast
System Software (Applied Biosystems). The comparative
threshold cycle (2–[delta] Ct) method, which converts dif-
ferences of cycle numbers to the ratio of the test gene/
control gene, was used to normalize the gene expression
levels to GAPDH mRNA.
PPI network and signaling pathway analysis
Proteins were analyzed for their interactions and signaling
pathways using Search Tool for the Retrieval of Interacting
Genes/Proteins (STRING) database version 9.0 (http://
string.embl.de) and the Ingenuity Pathways Analysis (IPA)
software (http://www.ingenuity.com), respectively.
Statistics
All statistical analyses were performed using the Student’s
t-test. Significance was defined as p < 0.05.
Additional files
Additional file 1: Figure 1. CO reduced the number of TRAP(+) cells in
bone marrow macrophages. Air+R, ordinary incubate condition (37°C, 5%
CO2) with MCSF 20 ng and RANKL 20 ng added; CO+R, ordinary incubate
condition plus CO, MCSF 20 ng and RANKL 20 ng.
Additional file 2: Figure 2. Positive control experiment with Calcitonin
30 nM and RANKL 20 ng in RAW cells.
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